密涅瓦神经科学公司(纳斯达克代码：NERV)空头股数更新

Minerva Neurosciences, Inc. (NASDAQ:NERV – Get Rating) was the target of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 197,300 shares, a decrease of 21.5% from the November 30th total of 251,300 shares. Currently, 4.3% of the company's stock are short sold. Based on an average daily volume of 308,100 shares, the days-to-cover ratio is currently 0.6 days.

Analyst Ratings Changes

Several analysts have recently issued reports on NERV shares. StockNews.com cut shares of Minerva Neurosciences from a "hold" rating to a "sell" rating in a research report on Friday, November 18th. JMP Securities cut shares of Minerva Neurosciences from an "outperform" rating to a "market perform" rating in a research report on Monday, October 17th. Finally, HC Wainwright cut shares of Minerva Neurosciences from a "buy" rating to a "neutral" rating in a research report on Thursday, November 10th.

Get Minerva Neurosciences alerts:

Institutional Trading of Minerva Neurosciences

A number of large investors have recently made changes to their positions in NERV. Renaissance Technologies LLC lifted its holdings in shares of Minerva Neurosciences by 185.9% during the third quarter. Renaissance Technologies LLC now owns 101,800 shares of the biopharmaceutical company's stock worth $940,000 after purchasing an additional 66,189 shares during the period. BlackRock Inc. increased its position in shares of Minerva Neurosciences by 54.7% in the third quarter. BlackRock Inc. now owns 78,086 shares of the biopharmaceutical company's stock valued at $721,000 after buying an additional 27,612 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Minerva Neurosciences in the third quarter valued at $231,000. Truist Financial Corp purchased a new position in shares of Minerva Neurosciences in the third quarter valued at $102,000. Finally, UBS Group AG increased its position in shares of Minerva Neurosciences by 914.5% in the third quarter. UBS Group AG now owns 5,732 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 5,167 shares in the last quarter. 38.00% of the stock is currently owned by hedge funds and other institutional investors.

Minerva Neurosciences Stock Performance

NERV stock opened at $1.59 on Monday. The company's 50 day moving average price is $2.98 and its 200 day moving average price is $4.96. Minerva Neurosciences has a fifty-two week low of $1.26 and a fifty-two week high of $15.27. The firm has a market capitalization of $8.49 million, a price-to-earnings ratio of -0.18 and a beta of -0.04.

About Minerva Neurosciences

(Get Rating)

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.

Read More

• Get a free copy of the StockNews.com research report on Minerva Neurosciences (NERV)
• MarketBeat: Week in Review 12/26 – 12/30
• The Dogs Of Tech: It's Time For A Bite Of These Stocks
• Does This Acquisition Make Microsoft a Bear Market Buy?
• Is Kintara Therapeutics A Hidden Gem?
• Should You Warm up to Generac Stock for the Winter?

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.